FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077981504> ?p ?o ?g. }

• W2077981504 endingPage "289" @default.
• W2077981504 startingPage "281" @default.
• W2077981504 abstract "Survivin-2B is reported to be specifically expressed in numerous malignant tissues. Furthermore, survivin-2B includes the epitope peptide (survivin-2B(80-88)) which is capable of binding to HLA-A24. In this study, we evaluated whether survivin-2B could be a novel vaccine target against lung cancer.(1) The differences in the survivin-2B expression between 15 sets of lung cancer tissues and normal lung tissues were investigated using RT-PCR. (2) The expression of survivin-2B was further examined in 42 lung cancer tissues, and the relationship between the expression and clinicopathologic factors was analyzed. (3) To compare the frequency of precursor CTL between survivin-2B positive and negative lung cancer patients, surivivin-2B(80-88) peptide-specific CTL were induced from regional lymph node lymphocytes (LNL) of four HLA-A24 (+) lung cancer patients, in whom two showed a positive survivin-2B expression of lung cancer while another two were negative, after stimulation with surivivin-2B(80-88).Survivin-2B was specifically expressed in lung cancer tissues, and was expressed in 17 of 42 lung cancer tissues (42.9%). Histologically, it was significantly more frequently expressed in squamous cell carcinoma than in adenocarcinoma (p=0.014). The frequency of precursor CTL in LNL was approximately one in 2.0 x 10(7) in patients with survivin-2B expression (-) lung cancer, however, it was one in 5.0 x 10(6) to 6.0 x 10(6) in those with survivin-2B expression (+) lung cancer.Survivin-2B was specifically expressed in lung cancer tissue, and found to specifically elicit a cellular immune response in lung cancer patients and therefore it may be a novel candidate for peptide vaccination." @default.
• W2077981504 created "2016-06-24" @default.
• W2077981504 creator A5004273623 @default.
• W2077981504 creator A5008849853 @default.
• W2077981504 creator A5013700595 @default.
• W2077981504 creator A5019175407 @default.
• W2077981504 creator A5021134164 @default.
• W2077981504 creator A5036867655 @default.
• W2077981504 creator A5047879551 @default.
• W2077981504 creator A5052578079 @default.
• W2077981504 creator A5056393014 @default.
• W2077981504 creator A5070371608 @default.
• W2077981504 creator A5082473280 @default.
• W2077981504 creator A5085344099 @default.
• W2077981504 creator A5091118998 @default.
• W2077981504 date "2005-05-01" @default.
• W2077981504 modified "2023-10-18" @default.
• W2077981504 title "Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy" @default.
• W2077981504 cites W1662899239 @default.
• W2077981504 cites W1900090888 @default.
• W2077981504 cites W1918156452 @default.
• W2077981504 cites W1968574304 @default.
• W2077981504 cites W1975559803 @default.
• W2077981504 cites W1993312546 @default.
• W2077981504 cites W1995541635 @default.
• W2077981504 cites W2006987944 @default.
• W2077981504 cites W2015805627 @default.
• W2077981504 cites W2026763255 @default.
• W2077981504 cites W2035523654 @default.
• W2077981504 cites W2042502745 @default.
• W2077981504 cites W2053508680 @default.
• W2077981504 cites W2061023053 @default.
• W2077981504 cites W2063511434 @default.
• W2077981504 cites W2077927974 @default.
• W2077981504 cites W2146744909 @default.
• W2077981504 cites W2147103876 @default.
• W2077981504 cites W2167490100 @default.
• W2077981504 doi "https://doi.org/10.1016/j.lungcan.2004.10.017" @default.
• W2077981504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15829330" @default.
• W2077981504 hasPublicationYear "2005" @default.
• W2077981504 type Work @default.
• W2077981504 sameAs 2077981504 @default.
• W2077981504 citedByCount "24" @default.
• W2077981504 countsByYear W20779815042012 @default.
• W2077981504 countsByYear W20779815042015 @default.
• W2077981504 countsByYear W20779815042019 @default.
• W2077981504 countsByYear W20779815042020 @default.
• W2077981504 crossrefType "journal-article" @default.
• W2077981504 hasAuthorship W2077981504A5004273623 @default.
• W2077981504 hasAuthorship W2077981504A5008849853 @default.
• W2077981504 hasAuthorship W2077981504A5013700595 @default.
• W2077981504 hasAuthorship W2077981504A5019175407 @default.
• W2077981504 hasAuthorship W2077981504A5021134164 @default.
• W2077981504 hasAuthorship W2077981504A5036867655 @default.
• W2077981504 hasAuthorship W2077981504A5047879551 @default.
• W2077981504 hasAuthorship W2077981504A5052578079 @default.
• W2077981504 hasAuthorship W2077981504A5056393014 @default.
• W2077981504 hasAuthorship W2077981504A5070371608 @default.
• W2077981504 hasAuthorship W2077981504A5082473280 @default.
• W2077981504 hasAuthorship W2077981504A5085344099 @default.
• W2077981504 hasAuthorship W2077981504A5091118998 @default.
• W2077981504 hasConcept C121608353 @default.
• W2077981504 hasConcept C126322002 @default.
• W2077981504 hasConcept C142724271 @default.
• W2077981504 hasConcept C147483822 @default.
• W2077981504 hasConcept C147969180 @default.
• W2077981504 hasConcept C167672396 @default.
• W2077981504 hasConcept C195616568 @default.
• W2077981504 hasConcept C203014093 @default.
• W2077981504 hasConcept C2775975398 @default.
• W2077981504 hasConcept C2776256026 @default.
• W2077981504 hasConcept C2777701055 @default.
• W2077981504 hasConcept C2777714996 @default.
• W2077981504 hasConcept C2781182431 @default.
• W2077981504 hasConcept C502942594 @default.
• W2077981504 hasConcept C71924100 @default.
• W2077981504 hasConceptScore W2077981504C121608353 @default.
• W2077981504 hasConceptScore W2077981504C126322002 @default.
• W2077981504 hasConceptScore W2077981504C142724271 @default.
• W2077981504 hasConceptScore W2077981504C147483822 @default.
• W2077981504 hasConceptScore W2077981504C147969180 @default.
• W2077981504 hasConceptScore W2077981504C167672396 @default.
• W2077981504 hasConceptScore W2077981504C195616568 @default.
• W2077981504 hasConceptScore W2077981504C203014093 @default.
• W2077981504 hasConceptScore W2077981504C2775975398 @default.
• W2077981504 hasConceptScore W2077981504C2776256026 @default.
• W2077981504 hasConceptScore W2077981504C2777701055 @default.
• W2077981504 hasConceptScore W2077981504C2777714996 @default.
• W2077981504 hasConceptScore W2077981504C2781182431 @default.
• W2077981504 hasConceptScore W2077981504C502942594 @default.
• W2077981504 hasConceptScore W2077981504C71924100 @default.
• W2077981504 hasFunder F4320320912 @default.
• W2077981504 hasIssue "2" @default.
• W2077981504 hasLocation W20779815041 @default.
• W2077981504 hasLocation W20779815042 @default.
• W2077981504 hasOpenAccess W2077981504 @default.
• W2077981504 hasPrimaryLocation W20779815041 @default.
• W2077981504 hasRelatedWork W147472336 @default.

• next